[ET Net News Agency, 12 January 2024] BOCI lowered its target price for Simcere Pharma
(02096) to HKD9.4 from HKD10.6 and maintained its "buy" rating.
The research house said in 2024, it expects Simcere to resume 19% topline growth, driven
by 20% sales growth of Sanbexin, continuously rapid sales ramp up of COSELA/Xiannuoxin,
and steady growth of Enweida. (RC)